



**S3 Fig.** Survival outcomes. Progression-free survival (PFS) (A) and overall survival (OS) (B) of the overall population. PFS (C) and OS (D) based on the atezolizumab plus bevacizumab treatment duration (short-term group [ $< 1$  year] vs. long-term group [ $\geq 1$  year]). CI, confidence interval; NR, not reached.